Document is current
Any future updates will be listed below
-
Authors
Robert, Philippe A. http://orcid.org/0000-0003-1345-5015
Akbar, Rahmad
Frank, Robert http://orcid.org/0000-0001-9097-7963
Pavlović, Milena http://orcid.org/0000-0002-2484-3868
Widrich, Michael http://orcid.org/0000-0002-5721-0135
Snapkov, Igor
Slabodkin, Andrei
Chernigovskaya, Maria
Scheffer, Lonneke http://orcid.org/0000-0001-8900-075X
Smorodina, Eva http://orcid.org/0000-0002-5457-5163
Rawat, Puneet
Mehta, Brij Bhushan http://orcid.org/0000-0002-8501-7076
Vu, Mai Ha http://orcid.org/0000-0002-9702-226X
Mathisen, Ingvild Frøberg
Prósz, Aurél
Abram, Krzysztof
Olar, Alex
Miho, Enkelejda
Haug, Dag Trygve Tryslew
Lund-Johansen, Fridtjof
Hochreiter, Sepp
Haff, Ingrid Hobæk
Klambauer, Günter
Sandve, Geir Kjetil http://orcid.org/0000-0002-4959-1409
Greiff, Victor http://orcid.org/0000-0003-2622-5032
-
Funding
Funding for this research was provided by:
Stiftelsen Kristian Gerhard Jebsen (Coeliac Disease Research Centre, Coeliac Disease Research Centre)
Norges Forskningsråd (#311341 IKTPLUSS, FRIPRO #300740, IKTPLUSS #311341)
Leona M. and Harry B. Helmsley Charitable Trust (#2019PG-T1D011)
EC | Horizon 2020 Framework Programme (iReceptorplus #825821)
Kreftforeningen (#215817)
- License Information
-
More Information
Article History
Received: 16 July 2021
Accepted: 9 November 2022
First Online: 19 December 2022
Competing interests
: E.M. declares holding shares in aiNET GmbH. V.G. declares advisory board positions in aiNET GmbH, Enpicom B.V, Specifica Inc, Adaptyv Biosystems, EVQLV, Omniscope, Diagonal Therapeutics, and Absci. V.G. is a consultant for Roche/Genentech, immunai, and Proteinea. The other authors declare no competing interests.
